Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women

References

• Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977; 4: 31–47
   PubMed Web of Science ®Google Scholar
• Whitehead M I. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas 1978; 1: 87–98
   PubMed Web of Science ®Google Scholar
• Voigt L F, Weiss N S, Chu J, Daling J R, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–277
   PubMed Web of Science ®Google Scholar
• Cullberg G, Knutsson F, Mattsson L -Å. A new combination of conjugated equine oestrogens and medroxyprogesterone for treatment of climacteric complaints. Maturitas 1984; 6: 55–63
   Google Scholar
• Gelfand M M, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol 1989; 74: 398–402
   PubMed Web of Science ®Google Scholar
• Woodruff J D, Pickar J H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213–1223
   PubMed Web of Science ®Google Scholar
• Persson I, Adami H -O, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147–151
   PubMed Web of Science ®Google Scholar
• Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999; 13: 316–326
   PubMed Web of Science ®Google Scholar
• Winneker R C, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003; 68: 915–920
   PubMed Web of Science ®Google Scholar
• Sherwin B B. Progestogens used in menopause. Side effects, mood and quality of life. J Reprod Med 1999; 44: 227–232
   Google Scholar
• Sherwin B B. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991; 72: 336–343
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Wahab M, Thompson J, Whitehead M, Thompson W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod 1999; 14: 636–641
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Wahab M, Thompson J, Pornel B, Hirvonen E, Ylikorkala O, van der Mooren M J, Dillon J, Magaril C. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 2001; 4: 343–354
   PubMedGoogle Scholar
• Bouali Y, Gaillard-Kelly M, Marie P J. Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia. Gynecol Endocrinol 2001; 15: 48–55
   PubMed Web of Science ®Google Scholar
• Lepescheux L, Secchi J, Gaillard-Kelly M, Miller P. Effects of 17β-estradiol and trimegestone alone, and in combination, on the bone and uterus of ovariectomized rats. Gynecol Endocrinol 2001; 15: 312–320
   PubMed Web of Science ®Google Scholar
• Meuwissen J H, Beijers-De Bie L, Vihtamaki T, Tuimala R, Siseles N, Magaril C, The H S, Houben P W, Murga M, Spielmann D, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecol Endocrinol 2001; 15: 349–358
   PubMed Web of Science ®Google Scholar
• Ross D, Godfree V, Cooper A, Pryse-Davies J, Whitehead M I. Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium. Maturitas 1997; 28: 83–88
   PubMed Web of Science ®Google Scholar
• Sultan E, Perret C, Verdier P, et al. Pharmacokinetics of estradiol and trimegestone in postmenopausal women after multiple administration of 2 mg estradiol once a day for 14 days followed by 2 mg estradiol/0.5 mg trimegestone once a day for 14 days. Climacteric 1999; 2: 221
   Google Scholar
• Warming L, Ravn P, Spielmann D, Delmas P, Christiansen C. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 2004; 11: 337–342
   PubMed Web of Science ®Google Scholar
• Marslew U, Riis B J, Christiansen C. Bleeding patterns during continuous combined estrogen–progestogen therapy. Am J Obstet Gynecol 1991; 164: 1163–1168
   PubMed Web of Science ®Google Scholar
• Odmark I -S, Jonsson B, Backstrom T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17β-estradiol and norethindrone acetate. Am J Obstet Gynecol 2001; 184: 1131–1138
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Spielmann D, Genazzani A R, Trimegestone 301 Study Group. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17β-estradiol and trimegestone versus two regimens containing 1 or 2 mg 17β-estradiol and noresthisterone acetate. Gynecol Endocrinol 2005; 21(2)65–73
   Web of Science ®Google Scholar
• Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg L -G. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164: 47–52
   PubMed Web of Science ®Google Scholar
• Nasri M N, Coast G J. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989; 96: 1333–1338
   PubMedGoogle Scholar
• Bjarnason N H, Christiansen C. The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 2000; 85: 590–596
   PubMed Web of Science ®Google Scholar
• Geisler J, Omsjo I H, Helle S I, Ekse D, Silsand T, Lonning P E. Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. J Endocrinol 1999; 162: 265–270
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products. Points to consider on hormone replacement therapy. European Agency for the Evaluation of Medicinal Products, London 1997
   Google Scholar
• Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275: 370–375
   PubMed Web of Science ®Google Scholar
• Pickar J H, Yeh I -T, Wheeler J E, Cunnane M F, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two year substudy results. Fertil Steril 2003; 80: 1234–1240
   PubMed Web of Science ®Google Scholar
• Sardo A D, Radhakrishnan S. Endometrial carcinoma on continuous combined HRT: case report and literature review. Maturitas 2004; 48: 171–175
   Google Scholar